French biopharma company Hybrigenics has made another bid to merge with Belgium's Bone Therapeutics, a specialist in regenerative medicine that is still recovering from a setback in its lea
Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinic
Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells.